Dyadic Q1 revenue up 50.9% YoY to $978K; net loss narrows to $956K

DYADIC INTERNATIONAL INC

Revenue of $978K (+50.9% YoY); net loss $(0.03)/share vs $(0.09) prior year.
Cash and securities $11.8M at Mar 31, 2023, down from $12.7M at Dec 31, 2022.
Received ~$1.27M from sale of minority stake in Alphazyme in Jan 2023.
DYAI-100 booster vaccine dosing completed; no serious adverse events; safety report due June 2023.
Expanded collaborations with Rubic One Health (Africa) and new top-5 pharma research.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

DYADIC INTERNATIONAL INC reported financial results for quarter ended March 31, 2023.

Period: quarter ended March 31, 2023
Result: reported results

Exact text from the filing

Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced its financial results for the first quarter of 2023, and highlighted recent company developments.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

DYADIC INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0001437749-23-013644

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.